Targeted quantitation of CFTR protein expression in vivo using immunoprecipitation & parallel reaction monitoring tandem mass spectrometry

Translational Medicine Communications - 2022
Hui Wang1, Yunxiang Dai1, Nicholas Clark1, Lianne Boeglin1, Caroline J. Woo1, Richard Wooster1, Gang Sun1, James C. Sullivan1
1Translate Bio, a Sanofi Company, Lexington, MA, 02421, USA

Tóm tắt

Abstract Background The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a low-abundance membrane protein. The dysfunction of CFTR protein is the fundamental cause of cystic fibrosis (CF), a fatal genetic disease. In recent years, the novel messenger RNA (mRNA)-based therapy shows high potential to treat CF disease, by delivering CFTR mRNA into lung epithelial cells to generate fully functional CFTR replacement protein. To evaluate mRNA drug efficacy, a targeted quantitative proteomics method is needed to estimate the expression level of mRNA encoded CFTR protein. Methods In this paper, a method combining membrane protein extraction, immunoprecipitation (IP), and nanoLC-MS/MS for quantifying CFTR in lung tissue samples was reported for the first time. Absolute quantification was performed by constructing a standard curve by spiking recombinant human CFTR protein in mouse lung tissue matrix. Results This method was qualified, with good linearity of standard curve and lower limit of quantification of human CFTR at 1.4 pg per mg tissue. The coefficient of variation of back calculated concentration of all standards and their back-calculation errors were < 20%. The CFTR expression level in mouse lungs dosed with mRNA encapsulated lipid nanoparticle (LNP), and the endogenous level in wild type human lungs were measured successfully. Conclusions The result demonstrated high sensitivity, precision and accuracy of this proteomics method for quantifying low-abundance CFTR protein in lung tissue sample.

Từ khóa


Tài liệu tham khảo

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou J, Drumm ML, Iannuzzi MC, Collins FS, Tsui LC. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066–73.

Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem. 2008;77:701–26.

Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015;16:45–56.

Mall MA, Hartl D. CFTR cystic fibrosis and beyond. Eur Respir J. 2014;44:1042–54.

Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan RC, Smith AE, Welsh MJ. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science. 1991;253:202–5.

Gadsby DC, Vergani P, Csanády L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature. 2006;440(7083):477–83.

Csanády L, Vergani P, Gadsby DC. Structure, gating, and regulation of the CFTR anion channel. Physiol Rev. 2019;99:707–38.

Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O’Riordan CR, Smith AE. Defective intracellular transport and processing of CFTR is the of most cystic fibrosis. Cell. 1990;63:627–34.

Mall M, Kreda SM, Mengos A, Jensen TJ, Hirtz S, Seydewitz HH, Yankaskas J, Kunzelmann K, Riordan JR, Boucher RC. The ΔF508 mutation results in loss of CFTR function and mature protein in native human colon. Gastroenterology. 2004;126:32–41.

Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Trends Mol Med. 2012;18(2):81–91.

Kumar P, Bhattacharyya S, Peters KW, Glover ML, Sen A, Cox RT, Kundu S, Caohuy H, Frizzell RA, Pollard HB, Biswas R. miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells. Gene Ther. 2015;22:908–16.

Neuberger T, Burton B, Clark H, Van Goor F. Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators. In: Amaral M, Kunzelmann K. Cystic Fibrosis. Methods Mol Biol. 2011;741:39–54.

Awatade NT, Uliyakina I, Farinha CM, Clarke LA, Mendes K, Solé A, Pastor J, Ramos MM, Amaral MD. Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis. EBioMedicine. 2015;2:147–53.

Bear CE. A therapy for most with cystic fibrosis. Cell. 2020;180:211.

Rafeeq MM, Murad HAS. Cystic fibrosis: current therapeutic targets and future approaches. J Transl Med. 2017;15:84.

Lee JA, Cho A, Huang EN, Xu Y, Quach H, Hu J, Wong AP. Gene therapy for cystic fibrosis: new tools for precision medicine. J Transl Med. 2021;19:452.

Jaques R, Shakeel A, Hoyle C. Novel therapeutic approaches for the management of cystic fibrosis. Multidiscip respir med. 2020;15:690.

Translate Bio, Inc. Translate Bio announces interim results from phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis. 2019. http://investors.translate.bio/node/7101/pdf.

Farinha CM, Mendes F, Roxo-Rosa M, Penque D, Amaral MD. A comparison of 14 antibodies for the biochemical detection of the cystic fibrosis transmembrane conductance regulator protein. Mol cell probes. 2004;18:235–42.

Farinha CM, Penque D, Roxo-Rosa M, Lukacs G, Dormer R, McPherson M, Pereira M, Bot AGM, Jorna H, Willemsen R, Jonge HD, Heda GD, Marino CR, Fanen P, Hinzpeter A, Lipecka J, Fritsch J, Gentzsch M, Edelman A, Amaral MD. Biochemical methods to assess CFTR expression and membrane localization. J Cyst Fibros. 2004;3:73–7.

Roxo-Rosa M, Davezac N, Bensalem N, Majumder M, Heda GD, Simas A, Penque D, Amaral MD, Lukacs GL, Edelman A. Proteomics techniques for cystic fibrosis research. J Cyst Fibros. 2004;3:85–9.

McClure M, DeLucas LJ, Wilson L, Ray M, Rowe SM, Wu X, Dai Q, Hong JS, Sorscher EJ, Kappes JC, Barnes S. Purification of CFTR for mass spectrometry analysis: identification of palmitoylation and other post-translational modifications. Protein Eng Des Sel. 2012;25(1):7–14.

Pankow S, Bamberger C, Calzolari D, Martínez-Bartolomé S, Lavallée-Adam M, Balch WE, Yates JR III. ΔF508 CFTR interactome remodeling promotes rescue of cystic fibrosis. Nature. 2015;528(7583):510–6.

Pankow S, Bamberger C, Calzolari D, Bamberger A, Yates IIIrd JR. Deep interactome profiling of membrane proteins by co-interacting protein identification technology (CoPIT). Nat Protoc. 2016;11(12):2515–28.

Jiang H, Ramos AA, Yao X. Targeted quantitation of overexpressed and endogenous cystic fibrosis transmembrane conductance regulator using multiple reaction monitoring tandem mass spectrometry and oxygen stable isotope dilution. Anal Chem. 2010;82:336–42.

McShane AJ, Bajrami B, Ramos AA, Diego-Limpin PA, Farrokhi V, Coutermarsh BA, Stanton BA, Jensen T, Riordan JR, Wetmore D, Joseloff E, Yao X. Targeted proteomic quantitation of the absolute expression and turnover of cystic fibrosis transmembrane conductance regulator in the apical plasma membrane. J Proteome Res. 2014;13:4676–85.

Farrokhi V, Bajrami B, Nemati R, McShane AJ, Rueckert F, Wells B, Yao X. Development of structural marker peptides for cystic fibrosis, transmembrane conductance regulator in cell plasma membrane by reversed-footprinting mass spectrometry. Anal Chem. 2015;87:8603–7.

Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4:222.

Fusaro VA, Mani DR, Mesirov JP, Carr SA. Prediction of high-responding peptides for targeted protein assays by mass spectrometry. Nat Biotechnol. 2009;27:190–8.

Picotti P, Aebersold R. Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions. Nat methods. 2012;9(6):555–66.

Saha K, Bender F, Gizeli E. Comparative study of IgG binding to proteins G and A: nonequilibrium kinetic and binding constant determination with the acoustic waveguide device. Anal Chem. 2003;75:835–42.

Haugland RP, You WW. Coupling of antibodies with biotin. In: McMahon RJ. Avidin-Biotin Interactions. Methods Mol Biol. 2008;418:13–24.

Chaptal V, Delolme F, Kilburg A, Magnard S, Montigny C, Picard M, Prier C, Monticelli L, Bornert O, Agez M, Ravaud S, Orelle C, Wagner R, Jawhari A, Broutin I, Pebay-Peyroula E, Jault JM, Kaback HR, Maire Ml, Falson P. Quantification of detergents complexed with membrane proteins. Sci Rep. 2016;7:41751.

Zhang H, Gu H, Shipkova P, Ciccimaro E, Sun H, Zhao Q, Olah TV. Immunoaffinity LC–MS/MS for quantitative determination of a free and total protein target as a target engagement biomarker. Bioanalysis. 2017;9(20):1573–88.

Thông tin
Thông tin xuất bản

Translational Medicine Communications

Thông tin tác giả